Identification of the DREAM transcriptional repression complex as a mediator of the differential response observed in EpCAM+/CD44+/CD166+ as compared to EpCAM+/CD44neg/CD166neg colon cancer cells following in vivo chemotherapy with irinotecan (CPT-11). This evidence concerns the gene ALCAM and malignant colon neoplasm.